OR8J3

Across TCGA pan-cancer cohorts, OR8J3 Mutation is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated OR8J3 data layer compared with 4 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher OR8J3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR8J3 expression acts as an unfavorable survival marker.

THYM, PAAD, and MESO are the cancer types where OR8J3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
PAAD	OS	Median	All	0.060	0.641	<.001	12	view →
MESO	DFS	Median	II,III,IV	0.039	0.407	<.001	12	view →
LGG	OS	Median	All	0.148	0.909	<.001	12	view →
GBM	OS	Median	All	0.062	0.416	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
KIRP	OS	Median	All	0.222	0.705	.035	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR8J3–THYM (OS)

Open the THYM breakdown →